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ABSTRACT: The acetylcholine-activated inward rectifier potassiumcurrent (IKACh) is constitutively active in persistent
atrial fibrillation (AF). We tested the hypothesis that the blocking of IKACh with the small molecule chloroquine
terminates persistent AF. We used a sheep model of tachypacing-induced, persistent AF, molecular modeling,
electrophysiology, and structural biology approaches. The 50% inhibition/inhibitory concentration of IKACh block
with chloroquine,measured bypatch clamp,was 1mM. In opticalmapping of sheep heartswith persistentAF, 1mM
chloroquine restored sinus rhythm. Molecular modeling suggested that chloroquine blocked the passage of a hy-
drated potassium ion through the intracellular domain of Kir3.1 (a molecular correlate of IKACh) by interacting with
residues D260 and F255, in proximity to I228, Q227, and L299. 1H 15N heteronuclear single-quantum correlation of
purified Kir3.1 intracellular domain confirmed the modeling results. F255, I228, Q227, and L299 underwent signif-
icantchemical-shiftperturbationsupondrugbinding.Wethencrystallizedandsolveda2.5 A˚X-raystructureofKir3.1
with F255Amutation. Modeling of chloroquine binding to the mutant channel suggested that the drug’s binding to
the pore becomes off centered, reducing its ability to block a hydrated potassium ion. Patch clamp validated the
structural and modeling data, where the F255A and D260A mutations significantly reduced IKACh block by chloro-
quine.With theuseofnumericalandstructuralbiologyapproaches,weelucidated thedetailsofhowasmallmolecule
couldblock an ion channel and exert antiarrhythmic effects. Chloroquinebinds the IKACh channel at a site formedby
specific amino acids in the ion-permeation pathway, leading to decreased IKACh and the subsequent termination of
AF.—Takemoto, Y., Slough, D. P., Meinke, G., Katnik, C., Graziano, Z. A., Chidipi, B., Reiser, M., Alhadidy, M.M.,
Ramirez, R., Salvador-Montañe´s, O., Ennis, S., Guerrero-Serna, G., Haburcak, M., Diehl, C., Cuevas, J., Jalife, J.,
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The acetylcholine-activated inward rectifier potassium
current (IKACh) is remodeled in humans with persistent
atrial fibrillation (AF) and in animal models of persistent
AF (1–5). IKACh flows through tetrameric sarcolemmal
channels formed by the Kir3.1 and Kir3.4 proteins. IKACh
activity is minimal in baseline physiology (6). Upon
parasympathetic stimulation, acetylcholine binds to the
G-protein-coupled muscarinic receptor (6). Subsequently,
the Gbg subunit docks directly into its binding sites on the
channel, leading to its activation (7–9). As IKACh is im-
portant for heart rate modulation on a beat-to-beat basis,
the on/off switching of the current is tightly regulated.
However, in persistent AF, IKACh is constitutively active,
irrespective of parasympathetic stimulation (3), leading to
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a net increase in the background inward rectifier current.
Previous reports showed that an increase of the inward
rectifier current results in shorteningof theactionpotential
duration (APD) and the subsequent formation of stable
electrical rotors, which activate the myocardium at high
frequencies and lead to fibrillation (10, 11). Therefore, the
blocking of IKACh in the setting of chronic/persistent AF
may be antiarrhythmic (12, 13). We aimed to elucidate the
structural basis of how chloroquine blocks IKACh and
whether it can terminate persistent AF. In sheep hearts
with persistent AF, we compared the electrophysiological
effects of chloroquine with those of tertiapinQ—a 21 resi-
duepeptideblockerof IKACh (14), initially isolated fromthe
European honeybee venom—on the dynamics of the ar-
rhythmia.We also used proteinNMR spectroscopy, X-ray
crystallography, and molecular modeling to investigate
the structural details of how a small molecule (chloro-
quine) blocks a potassium current (IKACh).
MATERIALS AND METHODS
Persistent AF sheep model
All animal procedures followed institutional guidelines. A dual
chamber pacemaker (St. Jude Medical, St. Paul, MN, USA) was
implanted inmale sheep (30–40kg)withabipolarpacing lead (St.
JudeMedical) attached to the right atrial (RA) appendage under
general anesthesia, as described previously (15, 16). A sub-
cutaneous loop recorder (insertable loop recorder, Reveal XT;
Medtronic, Minneapolis, MN, USA) was inserted parasternally
in apposition to the left atrium (LA). After a 4 wk period of
recovery from surgery, the RA was paced with an algorithm
consisting of 30 s pacing at 20 Hz, followed by 10 s sensing. The
pacemaker resumed pacing only if AF stopped, and sinus
rhythm was detected. This algorithm reliably generated
tachypacing-induced, self-sustained, persistent AF after 2 mo
of pacing (16). Persistent AF was defined as episodes lasting
.7 d without reversal to sinus rhythm.
Optical mapping
Hearts were removed via thoracotomy and connected to a
Langendorff perfusion system with recirculating oxygen-
ated (95% O2, 5% CO2) Tyrode’s solution at a constant flow
rate of 240 ml/min (36.5–37.5°C, pH 7.4). The Tyrode’s so-
lution composition (in millimolars) was the following: NaCl
130, KCl 4.0,MgCl2 1.0, CaCl2 1.8, NaHCO3 24, NaH2PO4 1.2,
glucose 5.6, and albumin 0.04 g/l. Blebbistatin 10 mM (Enzo
Life Sciences, Farmingdale, NY, USA) was used to reduce
motion. After an atrial trans-septal puncture, all of the vein
orifices were sealed, except for the inferior vena cava, which
was connected to a digital sensor and to an open-end cannula
to control the intra-atrial pressure. The pressure was kept at
5 cm H2O, resembling the diastolic LA pressure. Three
custom-made bipolar electrodes were placed on the top of
RA appendage, LA appendage, and the roof of LA. All re-
cordings were bipolar signals obtained with a sampling rate
of 1.0 kHz (DA100C; Biopac Systems, Goleta, CA, USA). The
voltage-sensitive dye, di-4-ANEPPS (100–200 mg), was ad-
ministered before imaging. [The imaging setup is drawn (see
Fig. 2A).] The emitted fluorescence (645 nm) on the epicardial
surfaces of the LA freewall andRA freewall was captured by
2 charge-coupled device (CCD) cameras (80 3 80 pixels, 600
frames/s; LittleJoe; SciMeasureAnalytical Systems,Decatur,
GA, USA). A third CCD camera was coupled to a rigid
borescope (90° view angle), introduced through an incision
in the left ventricle, passed across the mitral valve, and fo-
cused on the endocardial surface of the posterior LA (PLA).
This is similar to what has been done before (15, 16). Five
second movies of AF were recorded every 2 min during a
30 min period of baseline AF. Afterwards, we tested, for
15 min, the effects of 1 mM chloroquine or 0.1–0.2 mM
tertiapinQ on the dynamics of persistent AF in 5 and 6 hearts,
respectively.
APD and dominant frequency analyses in the
isolated sheep heart
Five secondopticalmovieswereacquiredduringconstantpacing
or during sustainedAF.Under constant pacing, action potentials
were recorded, and the APD was computed at 50 and 75% re-
polarization (APD50 and APD75) at the LA, PLA, and RA, before
and after drug application. DuringAF, dominant frequency (DF)
mapswere generated from the opticalmovies by performing fast
Fourier transform on the fluorescence signal time series, as de-
tailed earlier (15, 16).
Kir3.1 intracellular domain expression,
purification, and 1H 15N HSQC NMR spectroscopy
The DNA sequence for the Kir3.1 intracellular domain con-
sisting of residues 41–64 and 190–371, studied earlier with
X-ray crystallography and NMR (17–19), was synthesized
and cloned into the polyhistidine-tobacco etch virus-ligation-
independent cloning vector. Protein expression was induced
with 0.4mM isopropyl-b-d-(2)-thiogalactopyranoside for 8 h
at 25°C. To obtain the Kir3.1 protein in a uniform 1H/15N
background, as detailed in earlier NMR studies of the Kir3.1
intracellular domain (17, 20), transformed BL21(DE3)pLysS-
competent cells were grown to an optical density with a
wavelength of 600 nm of 0.9 at 37°C in M9 minimal medium.
The M9 medium contained 15NH4Cl (1 g/L), [U-
2H] glucose
(2 g/L), and [2H/15N] Celtone base powder (1 g/L) in 99%
2H2O (Cambridge Isotope Laboratories, Tewksbury, MA,
USA). Cells were harvested by centrifugation and frozen at2
80°C. The pellets were suspended in lysis buffer containing
20 mM Tris-HCl (pH 8.0), 200 mM NaCl, 0.1 mM DTT, leu-
peptin, and aprotinin and lysed by sonication. The lysates
were then centrifuged, and the supernatant was purified
using the Ni affinity column (Qiagen, Germantown, MD,
USA) and eluted in lysis buffer containing 300mM imidazole.
The polyhistidine-tag was then cleaved by tobacco etch virus
protease, and the cleaved protein was purified on a size-
exclusion chromatography column (HiLoad Superdex 200 pg;
GEHealthcare,Waukesha,WI,USA), pre-equilibrated in 10mM
HEPES-NaOH, pH7.0, 50mMKCl, and 1mMDTT.As in earlier
studies (17, 19, 20), thechromatograms indicated thatourprotein
traveled as a tetramer in solution. The NMR samples were con-
centrated to ;0.25 mM tetrameric Kir3.1 in a buffer containing
10 mM HEPES-NaOH, pH 7.0, 50 mM KCl, and 1 mM DTT in
90%H2O/10%
2H2O.
1H 15N two-dimensional spectra of Kir3.1
were collected in the absence and presence of 1mMchloroquine
(Sigma-Aldrich, St. Louis, MO, USA) on a Burker DRX-600 with
a cryoprobe using a transverse relaxation optimized spectros-
copy (TROSY)-heteronuclear single-quantum correlation
(HSQC) sequence. Spectra were processed with nmrPipe
software (21). The processing scheme consisted of a solvent-
suppression filter, cosine square-bell apodization function,
0 filling to double number of points, and phase correction in
both dimensions: baseline correction in the first dimension
and linear prediction in seconddimension. Spectrawere analyzed
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using CcpNmr software (22). Assignments were transferred from
the published chemical shifts for Kir3.1 (20) (Biological Magnetic
Resonance Data Bank Accession Number: 11067). Out of 187
backbone amides with published 1H 15N chemical shifts, 156
peaks could be picked in the Kir3.1 protein-alone spectrum above
noise level.One residue (F46)wasoutsideof the 1Hspectralwidth.
Assignments were then transferred from the Kir3.1 protein-alone
spectrum to the Kir3.1 + chloroquine spectrum, where the closest
peaks in the ligand-bound spectrumwere assumed tobe the same
residues, as in the Kir3.1-alone spectrum. One hundred thirty
peaks could be transferred from the Kir3.1 protein alone to the
chloroquine-boundspectrum.Most of thepeaksmissingare likely
a result of a low signal-to-noise ratio except forQ360,Q363,M364,
M367, S368, and S369, which are likely a result of ligand-induced
intermediate chemical exchange, as they are located in the very
distal C-terminal helix of Kir3.1.
Chemical shift perturbations (CSPs)were calculated for peaks
in the Kir3.1 alone and chloroquine-bound spectra using
CcpNmr, according to the following equation:
CPS ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
Dd2HNþð0:15DdNÞ2
q
whereDdHN andDdN are the changes in chemical shift of
1H and
15N during complex formation measured in parts per million.
Transferred chemical shifts are reported inSupplemental Table 1.
Patch clamp and immunofluorescence
Patch pipettes were pulled from borosilicate glass tubes (World
Precision Instruments, Sarasota, FL, USA), 2–3 MV resistance.
Gigaohmseal andwhole-cell recordingswereperformedat room
temperature. The bath solution contained the following (in mil-
limolars): 90 NaCl, 50 KCl, 1 CaCl2, 2 MgCl2, 10 HEPES, 10 glu-
cose, pH7.4,withNaOH. The pipette internal solution contained
the following (in millimolars): K-aspartate 100, NaCl 10, KCl 40,
Mg-ATP 5, EGTA 2, GTP-Tris 0.1, HEPES 10, pH 7.4. IKACh cur-
rents inhumanembryonickidney293 (HEK293) cells, transfected
with Kir3.1 and Kir3.4 in the presence and absence of different
dosesof chloroquine (Sigma-Aldrich)or tertiapinQ(Tocris),were
evoked in response to a 2 s ramp from 2140 to 30 mV from a
holding potential of 0 mV and subtracted from the residual
current remaining after addition of 1 mM BaCl2 to the bath
solution. Currents were also evoked in HEK293 cells trans-
fected with either Kir3.1 and Kir3.4 or F255A or D260A
mutant Kir3.1 (introduced viaQuikChangemutagenesis and
verified by sequencing) and Kir3.4 in the presence and ab-
sence of chloroquine. For fluorescence imaging, cells were
plated on a coverslip and stained for 10 s with tertiapinQ-
ATTO-488 (Alomone Laboratories, Jerusalem, Israel), and
then images were acquired using an Olympus FV1000 mul-
tiphoton laser-scanning microscope.
Cloning, overexpression, and purification of the
F255A Kir3.1 mutant
TheKir3.1 construct used for crystallizationwas the same as
that used for the NMR experiment described above. The
F255A mutation was introduced via QuikChange muta-
genesis and verified by sequencing. The plasmid contain-
ing Kir3.1 F255Awas transformed into Escherichia coli BL21
(DE3) cells. The cells were grown at 37°C in 2 3 YT media
containing ampicillin. At an optical density at 600 nm of
;0.5, the temperature was lowered to 18°C. After 30 min at
18°C, isopropyl b-D-1-thiogalactopyranoside was added to
a final concentration of 100 mM. Cells were harvested 16–20 h
after induction by centrifugation at 4°C for 20 min. Cell
pellets from 6 L culture were resuspended in 100 ml lysis
buffer (20 mM Tris, pH 8.5, 150 mM NaCl, 1 mM PMSF,
1 mg/ml aprotinin) and stored at 280°C until ready for
processing. All protein purification was performed on ice
or at 4°C. The cells were lysed with 3 passes through an
EmulsiFlex-C5 microfluidizer (Avestin, Ottawa, ON, Can-
ada). The lysate was spun down at 35,000 rpm in an ultra-
centrifuge Ti70 rotor. The supernatant was loaded onto the
Ni affinity column (Qiagen), pre-equilibrated in buffer
(20 mM Tris, pH 8.5, 10 mM imidazole, 150 mM NaCl,
0.1 mM PMSF, 1 mg/ml aprotinin). After sufficient washing
in the previous buffer, the bound protein was eluted
(20 mM Tris, pH 8.5, 300 mM imidazole, pH 8.0, 150 mM
NaCl, 0.1 mM PMSF, 1 mg/ml aprotinin). The Kir3.1 F255A
fractions were analyzed by SDS-PAGE and pooled. The
pooled fractions were diluted to a final NaCl concentration
of 100 mM and loaded onto an anion exchange column
(Source 15Q; GEHealthcare), pre-equilibrated in buffer QA
(20 mM Tris, pH 8.0, 0.1 mM PMSF, 1 mM EDTA, 0.1%
2-ME). The protein was eluted using a gradient from buffer
QA to QB (QA + 1 M NaCl; no EDTA). The peak fractions
were analyzed by SDS-PAGE, and Kir3.1 F255A fractions
were pooled. The purified protein was concentrated, buffer
exchanged into storage buffer (20 mM Tris, pH 8.0, 150 mM
NaCl, 0.1% 2-ME, 5% glycerol), flash frozen in liquid ni-
trogen, and stored at 280°C.
Crystallization of Kir3.1 F255A and X-ray
data collection
The protein was concentrated to 10mg/ml and crystallized at
4°C in Linbro trays using the vapor-diffusion method by
mixing equal amounts of protein and reservoir solution
(25 mM Na/K phosphate, pH 5.0, 40 mM NaCl, 35% poly-
ethylene glycol 400). The mixture was allowed to equilibrate
over 1 ml reservoir solution. Crystals of Kir3.1 F255A were
harvested and transferred to a cryogenic solution (reservoir +
10–15% ethylene glycol), flash frozen in liquid nitrogen, and
stored in liquid nitrogen until ready for data collection. X-ray
data were collected at 100K at a wavelength of 1.0003 A˚ at the
Advanced Light Source Beamline 8.2.1 (Lawrence Berkeley
National Laboratory, Berkeley, CA, USA). X-Ray data were
reduced with the programs HKL2000 andMOSFLM (23). The
crystals grew in the space-groupP4212with a unit cell of 80.07,
80.07, 85.04 A˚; 90, 90, 90°, and 1 monomer in the asymmetric
unit.
Structure determination and refinement
The Kir3.1 F255A structure was solved by molecular re-
placement using the program Phaser (24) within the CCP4
suite (25) of crystallographic programs. The wild-type (WT)
Kir3.1 structure (18) [Protein Data Bank identification (PDB
ID): 1N9P] was used as a search model. A large negative-
difference density peak confirmed the F255A mutation.
Refmac5 (26) and Phenix (27) were used to refine the structure
at different stages. The molecular graphics program Coot (28)
was used formanual rebuilding between successive rounds of
refinement. PDB_REDO (29) was used to check for model
errors. The final model contains aa 43–63 and 190–370. The
final RWork and RFree were 22.39 and 26.68, respectively.
F255AmutantKir3.1 coordinateswere deposited into the PDB
(PDB ID: 5UM4). PyMOL (PyMOL Molecular Graphics Sys-
tem, v1.7.4; Schro¨dinger, Cambridge, MA, USA) was used for
visualization and generation ofmolecular figures. Themutant
was comparedwithWT structures (PDB IDs: 1N9P and 1U4E)
using the program PDBeFOLD (30).
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Molecular docking of chloroquine to Kir3.1
The intracellular domain of Kir3.1 (PDB ID: 1U4E) (19) and the
Kir3.1 F255A structure obtained here were used for the
docking simulations of the WT and mutant channels, re-
spectively. The chloroquine SMILES stringwas obtained from
DrugBank (31) (Accession Number: DB00608). The proteins
and chloroquine were prepped using the Protein Preparation
Wizard and LigPrep in Schrodinger’s Maestro (32). The pro-
tonation state of chloroquine was generated at a target pH of
7.0 using Epik (33, 34). The ligand was energy minimized
using the OPLS_2005 forcefield (35). Before docking, the
nonpolar hydrogens on both the protein and ligand were
merged. To prepare the proteins for docking, a set of gridswas
created mapping the protein topology. The grids were gen-
erated using 60 3 60 3 60 points in the x, y, and z directions
and centered around the aqueous channel with a spacing of
0.375 A˚. Subsequently, the Lamarckian genetic algorithmwas
used for docking. The population size was set to 150, the
number of energy evaluations was set to 2,500,000, and the
number of generations was set to 27,000. One thousand runs
were performed using AutoDock 4.2 (36). The lowest energy
poses from molecular docking were analyzed. Hydrogen
bond analysis was performed using Visual Molecular
Dynamics (37).
Estimation of blocking ability of chloroquine
The atomic coordinates of tetrameric WT or F255A mutant
Kir3.1 bound to chloroquine were transformed into a voxel
grid. In this grid, each voxel was a cube of 0.2 3 0.2 3 0.2 A˚.
Each atom filled a number of cubes corresponding to its van
derWaals radius (38). The use of the discrete grid allowed for a
probe to search the space in the aqueous ion-permeation
pathway. The probes used were voxel-approximated spheres
with radii ranging from 1.4 A˚ (corresponds to the ionic radius
of a bare K+ ion) to.3.9 A˚ (3.0 A˚ is the radius of a solvated K+
ion up to its first hydration shell) (39) in 0.1 A˚ increments. The
probes were started toward the extracellular opening of the
channel and were pushed longitudinally through the channel
toward the opposite side. If, at any point in the pathway, the
probe was unable to proceed further, then the probe’s lateral
position was adjusted so as to search all possible paths
through the channel. If the probe was physically unable to
move past chloroquine (i.e., no path was found), then the
channel was considered blocked at that probe radius.
RESULTS
Dose-response curve of IKACh block by
chloroquine and tertiapinQ
In HEK293 cells stably transfected with Kir3.1 and Kir3.4,
wemeasured the 50% inhibition/inhibitory concentration
(IC50) of IKACh block by chloroquine and tertiapinQ.
Figure 1A is a confocal image, showing the membrane
staining of IKACh proteins by tertiapinQ conjugated to the
fluorescent tag ATTO-488 in blank and in Kir3.1- and
Kir3.4-expressing HEK293 cells. Figure 1B patch-clamp
traces are currents in response to a 2 s voltage ramp (from
2140 to +30 mV), showing BaCl2-sensitive IKACh. The
current decreased by ;50% upon addition of 1 mM chlo-
roquine or 0.1 mM tertiapinQ. Figure 1C is the dose-
response relationship for the block of IKACh by tertiapinQ
and chloroquine. The IC50 for chloroquine is 1.02mM,R
2 =
0.96, and that of tertiapinQ is 0.07 mM, R2 = 0.94.
Chloroquine terminates persistent AF in the
sheep heart
The cardiac IKACh is a heterotetrameric channel formed by
Kir3.1 and Kir3.4 proteins (6). Our earlier study suggested
that chloroquine terminates cholinergic AF by blocking
IKACh (40). However, it is not known whether chloroquine
can terminate persistent AF. The effects of chloroquine in
persistent AF were investigated using optical mapping in
isolate Langendorff-perfused hearts. AF was easily rein-
ducedbyelectricalpacing inall exvivohearts (n=5)andwas
sustained throughout the 30min baseline recording. Before
and after the application of 1 mM chloroquine, 2.5 Hz con-
stant pacing was applied to assess the effect of the drug on
the APD. As shown in Fig. 2B, 1 mM chloroquine signifi-
cantly prolongedAPD75 in LA epicardium (LAepi; 125.76
9.9 ms before chloroquine, 159.4 6 10.7 ms after chloro-
quine, P , 0.01), RA epicardium (RAepi; 184.1 6 8.0 ms
before chloroquine, 208.4 6 9.7 ms after chloroquine, P ,
0.01), and PLA endocardium (PLAendo; 158.3 6 7.2 ms
before chloroquine, 180.6 6 9.3 ms after chloroquine, P ,
0.01). APD50 was also prolonged in LAepi (86.7 6 8.0 ms
before chloroquine, 114.4 6 6.8 ms after chloroquine, P ,
0.01), RAepi (139.66 7.9ms before chloroquine, 152.36 7.7
ms after chloroquine, P, 0.01), and PLAendo (123.56 9.2
ms before chloroquine, 137.5 6 8.7 ms after chloroquine,
P,0.01).RepresentativemapsofDFatbaselineandduring
chloroquine perfusion showed that in the presence of
chloroquine, DF was decreased in PLA, LA, and RA com-
paredwith baselineAF, untilAF spontaneously terminated
(Fig. 2C). The time course of maximal DF in all 5 experi-
ments is shown in Fig. 2D. Before the administration of
chloroquine, theDFwas8.460.7Hz inPLAendoand7.66
0.8Hz in LAepi, higher than in RAepi (6.96 0.9Hz). Upon
1 mM chloroquine perfusion, maximal DF significantly de-
creased to 5.36 0.7, 5.36 0.7, and5.36 0.7Hz inPLAendo,
LAepi, and RAepi (P , 0.05), just before resumption of
sinus rhythm (SR). In 5/5 hearts, AF terminated, and SR
resumed after 8.46 1.9 min of drug perfusion.
Effects of tertiapinQ on persistent AF in the
sheep heart
To confirm further that the antiarrhythmic effects of
chloroquine are, in part, as result of IKACh block, we tested
0.1–0.2mM tertiapinQ in 6 isolated Langendorff- perfused
sheep hearts with persistent AF. Sustained AF was easily
inducible by pacing in all ex vivo hearts. Initially, 0.1 mM
tertiapinQwas added to the perfusate, and after 15min, if
persistent AF was still present, then the peptide’s con-
centration was increased to 0.2 mM for another 15 min.
Four out of six hearts (67%) reverted to SRwith tertiapinQ
application (0.1mM: 1 heart, 0.2mM: 3 hearts). Two hearts
did not spontaneously convert to SR at 0.2mM tertiapinQ;
AF was cardioverted with a direct current shock. As
depicted Fig. 3A, the 4 hearts that converted to SR (n = 4),
pacing at 2.5 Hz, showed that tertiapinQ significantly
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prolonged APD75 in LAepi (106.0 6 10.1 ms before ter-
tiapinQ, 137.86 17.3ms after tertiapinQ,P=0.015), RAepi
(154.5 6 17.6 ms before tertiapinQ, 196.3 6 10.5 ms after
tertiapinQ, P = 0.018), and PLAendo (126.36 13.5 ms be-
fore tertiapinQ, 173.56 18.9ms after tertiapinQ,P, 0.01).
APD50 was also prolonged in LAepi (77.36 9.5 ms before
tertiapinQ, 100.1 6 12.9 ms after tertiapinQ, P , 0.01),
RAepi (109.3 6 7.9 ms before tertiapinQ, 148.3 6 9.3 ms
after tertiapinQ, P , 0.01), and PLAendo (86.86 10.6 ms
before tertiapinQ, 122.1 6 15.5 ms after tertiapinQ, P ,
0.01). Representative examples of DF maps during tertia-
pinQperfusion showed thatDFdecreased comparedwith
baseline AF and that AF spontaneously converted to SR
(Fig. 3B). The time course of maximal DF is shown in Fig.
3C. DF in PLA, LA, andRAat baselinewas 9.36 0.8, 8.86
0.5, and 7.76 0.4 Hz before administration of tertiapinQ.
The peptide significantly decreased maximal DF to 6.76
0.9, 6.4 6 0.8, and 5.2 6 0.6 Hz (P , 0.05), respectively,
immediatelybeforeAF termination (Fig. 3D;n=4). In the 2
hearts where AF did not terminate, tertiapinQ tended to
prolong theAPDand slowdown theDFof the arrhythmia
(Supplemental Fig. 1), however, to a lesser extent than in
the cases where AF terminated.
Docking of chloroquine in the tetrameric
Kir3.1 intracellular domain
The cardiac IKACh is a heterotetrameric channel formed
by Kir3.1 and Kir3.4 proteins (5). The structure of Kir3.4
has not been elucidated; however, that of the Kir3.1
intracellular domain has been studied with X-ray
crystallography and NMR spectroscopy (17, 18). Chlo-
roquine docking into the Kir3.1 intracellular aqueous
channel is shown in Fig. 4. One thousand docking runs
were performed. The 2 lowest energy poses were ana-
lyzed. Figure 4A, top, is a magnified view of the tetra-
meric Kir3.1 channel, represented by gray ribbons, with
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Figure 1. Determination of the IC50 for chloroquine
and tertiapinQ block of IKACh in HEK293 cells stably
transfected with Kir3.1 and Kir3.4. A) Confocal
microscopy. Fluorescence staining of IKACh pro-
teins. Upper: Live HEK293 cells transfected with
mCherry. TertiapinQ (TPQ) ATTO-488 does not
show staining. Lower: HEK293 cells, transfected
with mCherry and stably expressing Kir3.1/Kir3.4,
show robust staining of the cell membranes by
tertiapinQ ATTO-488. Laser and detector settings
were identical in both cases. B) IKACh recorded in
HEK293 cells expressing Kir3.1/3.4 in response to a
ramp in the absence and the presence of 1 mM
chloroquine (CQ) or 0.1 mM tertiapinQ. C) Dose-
response curve of IKACh block by chloroquine, IC50 =
1.02 mM, R2 = 0.96; TertiapinQ, IC50 = 0.07 mM, R
2 =
0.94.
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docked chloroquine in cyan (lowest energy pose). The
amine nitrogen of chloroquine formed ahydrogen bond
(red line) with the side chain of residue D260 on 1
subunit, whereas the aminoquinoline ring underwent
an aromatic–aromatic interaction with residue F255
from the adjacent subunit. The drug extended through
the horizontal plane of the aqueous channel at the level
of the D260/F255 residues. Figure 4B, top, is a view of
the tetrameric Kir3.1 channel, represented by gray rib-
bons, with docked chloroquine in cyan (second-lowest
energy pose). The amine nitrogen of chloroquine
formed a hydrogen bond (red line) with the carbonyl
oxygen chain of residue F255 on 1 subunit, whereas the
aminoquinoline ring underwent an aromatic–aromatic
interaction with residue F255 from the opposing sub-
unit. In Fig. 4, the drug extended through the horizon-
tal plane of the aqueous channel at the level of the
D260/F255 residues. The van der Waals representa-
tions of the Kir3.1:chloroquine complex are shown from
intracellular (middle) and extracellular (bottom) bird’s-
eye views, with the ion-permeation pathway in the
middle and chloroquine in cyan.
Kir3.1 interaction with chloroquine studied
with 1H 15N HSQC NMR
To validate the modeling data and delineate the binding
site of chloroquine, we studied the interaction of chloro-
quine with the purified intracellular domain of Kir3.1
using NMR spectroscopy. We acquired 1H 15N HSQC
spectra of theKir3.1 tetramer at a concentrationof 0.25mM
and then added 1 mM chloroquine and acquired the
spectra once again. Spectral analysis of the hydrogen and
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Figure 2. Effect of chloroquine on persistent AF in isolated Langendorff-perfused hearts. A) Ex vivo epicardial and endocardial
mapping setup includes 3 synchronized CCD cameras: cameras 1 and 2 for the epicardial imaging of the LA and RA and camera
3 coupled to an endoscope advanced through the left ventricle into the LA for endocardial PLA imaging. B) APD75 and APD50 at
constant 2.5 Hz pacing in PLA, LA, and RA, before and after the application of 1 mM chloroquine (n = 5). C) Representative DF
maps of the PLA, LA, and RA in baseline AF and 2 and 4 min after chloroquine 1 mM perfusion. After 4 min, the heart
spontaneously reverted to a 1.2 Hz SR. D) Time course of the average DF in the 5 hearts, 30 min before and after chloroquine
perfusion. The black 3marks indicate the time of spontaneous AF cardioversion in each of the hearts. E) Average maximum DF
right before chloroquine application at baseline and immediately before AF termination. *P , 0.05, **P , 0.01.
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nitrogen dimensions identified backbone residues with
significant CSPs .0.04 ppm as a result of chloroquine
binding. The transferred chemical shifts are reported in
Supplemental Table 1. In total, 11 backbone residues un-
derwent a significant difference in chemical shifts after
chloroquine binding to the channel. Theywere (largest to
smallest CSP) the following: L246,Q227,Q344,V47,K208,
H57, S235, L299, I228, L251, andG51.TheF255peak in the
spectrum of Kir3.1 alone was apparent above noise level.
After addition of chloroquine, at noise level, there was a
discernible peak corresponding to F255, which was sig-
nificantly shifted, suggesting that this residue’s chemical
environment has changed as a result of chloroquine
binding. Residue D260 did not undergo significant CSP.
However, this residue is linked via hydrogen bonding to
residue I228, which underwent CSP. It should be noted
that the TROSY-HSQC NMR sequence, which was used
here, is an indirect method that does not provide actual
structural restraints. The chemical shifts suggest the gen-
eral location of the binding pocket. Figure 5A shows ex-
amples of backbone resonances, with andwithout bound
chloroquine. The resonance contours ofKir3.1 alone are in
black, whereas those of Kir3.1, in the presence of chloro-
quine, are in red. ResiduesW323 andK49 are examples of
amino acid resonance contours that were unaffected by
chloroquine. I228 and L299 are examples of residues that
were affected by the drug. We subsequently mapped the
backbone residues with significant CSP onto the tetra-
meric structure of Kir3.1 (PDB ID: 1U4E) and highlighted
them in red (Fig. 5B). V47 and G51 are located adjacent to
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one another in a loop belonging to the N-terminal region.
H57 is located at the end of the N-terminal cytoplasmic
region, and K208 is located at the start of the b-strand bC
close to the distal C-terminal a helix aB region of the
Kir3.1 structure that contains the residues Q360, Q363,
M364, M367, S368, and S369 connected to each other via
hydrogen bonding. F255 and Q227 are located in the
aqueous pore region, and I228 is in the b-sheet bD, along
with Ser235, adjacent to the aqueous channel. I228 and
L299 are connected through a hydrogen-bond network
withL299, located at thebase of theG-loop inbH,a region
important for gating of the channel. Importantly, residues
Q227, I228, F255, and L299 form a pocket in the channel’s
aqueous vestibule. Figure 5C shows the channel’s longi-
tudinal viewof the vanderWaals representation,with the
2 front subunits removed, to expose this binding pocket
(circled in white). We then proceeded to combine the
NMR experimental results, with the molecular docking
shown in Fig. 4B. The binding pose of chloroquine from
Fig. 4B placed the drug into the pocket, suggested by the
1H 15NHSQCNMRspectra (Fig. 5D–F). The bindingpose
of chloroquine from Fig. 4A also places the drug into the
pocket, suggested by the 1H 15N HSQC NMR spectra
(data not shown).
X-Ray crystallography and structure
determination of the Kir3.1 intracellular
domain with F255A mutation
Weexplored thebindingof chloroquine toKir3.1 in further
structural detail.Wemutated residue F255 into an alanine
(F255A) and proceeded to express, purify, crystallize, and
solve a high-resolution X-ray structure of the F255A
channel. X-Ray datawere collected at the Advanced Light
Source Beamline 8.2.1 (Lawrence Berkeley National Lab-
oratory). The Kir3.1 protein with the F255A mutation
crystallized in the P4212 space group with 1 monomeric
Kir3.1 subunit in the asymmetric unit. A 2.5 A˚ resolution
structure was determined. The data collection and re-
finement statistics are in Supplemental Table 2. The mu-
tation introduced minimal changes into the overall
BA
Extracellular
Intracellular
D260
F255
F255
F255
Figure 4. Docking of chloroquine in the ion-
permeation pathway of the Kir3.1 channel. A,
B) Two lowest energy poses. Top: magnified
view of the binding poses of chloroquine (cyan
sticks) in Kir3.1. The D260 and F255 residues
from each of the 4 Kir3.1 subunits are shown in
green and orange sticks, respectively. A) The
amine nitrogen of chloroquine forms a hydro-
gen bond (red line) with the side chain of
D260 in 1 subunit, whereas the aminoquinoline
ring of chloroquine is involved in an aromatic–
aromatic interaction with the phenylalanine
ring of F255 in the adjacent subunit. B) The
amine nitrogen of chloroquine hydrogen
bonds (red line) the carbonyl oxygen of F255
in 1 subunit, whereas the aminoquinoline ring
of chloroquine is involved in an aromatic–
aromatic interaction with the phenylalanine
ring of F255 in the opposing subunit. Middle,
bottom: van der Waals representations of the
channel bound to chloroquine (cyan), viewed
from the intracellular and extracellular sides,
respectively.
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structure of the channel compared with the 2 previously
solvedWT structures (PDB IDs: 1N9P and 1U4E) (18, 19).
After molecular replacement with PDB ID 1N9P as a
search model (18), the electron density map for the Kir3.1
F255A tetrameric channel was generated. The difference
(Fo-Fc) electron density map, around the area of residue
255, contoured in red at 23 s, is shown in Fig. 6A. The
magnifiedviewof the residue255 region from1subunit in
Fig. 6A, right, highlights the red negative-density blob,
which indicates the absence of phenylalanine at position
255. Subsequently, we repeated the molecular modeling
experiments similarly to Fig. 4, by docking chloroquine in
the F255A mutant Kir3.1 channel. One thousand runs
were performed, and the lowest energy pose was ana-
lyzed. Figure 6B is a magnified view of the tetrameric
F255A Kir3.1 channel, represented by gray ribbons, with
docked chloroquine in cyan. The amine nitrogen of chlo-
roquine formed a hydrogen bond with the side chain of
D260. The drug binding is off centered and tucked be-
tween 2 subunits. The vanderWaals representation of the
F255A mutant channel bound to chloroquine (cyan) is
viewed from the intracellular side of Fig. 6B, right.
Modeling and quantification of chloroquine
block in WT and F255A mutant Kir3.1
Figure 7A is a magnified view of chloroquine docked in
WT and mutant Kir3.1, where the drug’s ability to block
the channel might be reduced by the absence of residue
F255. Consequently, we quantified chloroquine’s block-
ing ability of theWTandmutant channels. Figure7B is the
voxelated ion-permeation pathway in the WT channel
bound to chloroquine. It was found that a probe of
radius $2.5 A˚ was blocked by the drug, and probes
with radii #2.5 A˚ passed through. Figure 7C is the
A C
E
W323 I228
K49 L299
L299
B
Q227
I228
D F
Q227
I228
F255
F255
L299
F255
Figure 5. Chloroquine binding to the isolated and purified Kir3.1 intracellular domain studied with 1H 15N HSQC NMR. A)
Examples of resonance peaks of residues W323, K49, I228, and L299 obtained by a 1H 15N NMR TROSY-HSQC sequence. The
black contours are of the Kir3.1 protein alone, and the red contours are after addition of chloroquine. The resonance peaks of
W323 and K49 did not undergo significant shifts, suggesting that these residues are not involved in the binding of chloroquine to
the channel. The peaks of I228 and L229 underwent significant shifts, indicating that the chemical environment of these residues
have changed upon chloroquine binding to the channel. B) An intracellular bird’s-eye view of the tetrameric Kir3.1 is shown in
gray ribbons, whereas the residues that underwent significant CSPs in the NMR experiments are shown as red sticks. C) A
longitudinal representation of the tetrametric channel, with the front 2 subunits removed, exposing the amino acids (Q227, I228,
F255, and L299) that form a binding pocket for chloroquine (white circle) in the aqueous vestibule. D) Placement of docked
chloroquine in the binding pocket suggested by NMR. Longitudinal view of chloroquine (cyan sticks) docked into the Kir3.1
channel from Fig. 4 with the front subunits removed, and the residues that underwent significant shifts in the NMR experiment
are shown in red. E) Magnified view of the boxed area in D showing agreement between the molecular docking of chloroquine
and the binding pocket suggested by NMR, with chloroquine sitting in the NMR-suggested binding site. F) Chloroquine in cyan
sticks is shown with the amino acids that underwent CSPs in NMR, depicted in red sticks.
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voxelated ion-permeation pathway in the F255A
mutant channel bound to chloroquine. The drug was
unable to block a probe of radius 2.5 A˚, and the minimal
radius of block occurred at 3.9 A˚. We validated the
numerical and structural data in patch-clamp experi-
ments.HEK293 cellswere transfectedwithWTKir3.1 or
F255A or D260A Kir3.1 and with Kir3.4. The mutant
IKACh channels were expressed at the cell membrane
(Fig. 8A). We then constructed dose-response curves
of chloroquine block of the WT and mutant currents
elicited by a ramp from 2140 to 30 mV. The current-
voltage relationships are in Fig. 8B, where the muta-
tions reduced the ability of 1 mM chloroquine to block
the BaCl2-sensitive current. Figure 8C, left, shows dose-
response curves for the effect of chloroquine on the BaCl2-
sensitive inward current, measured at2120 mV, where
the IC50 for WT was significantly lower (0.8 mM, R
2 =
0.81, n = 11) than F255A (3.2 mM, R2 = 0.75, n = 10) and
D260 (2.8mM,R2 = 0.9, n= 10;P, 0.01). Figure 8C, right,
dose-response curves for the effect of chloroquine on
the BaCl2-sensitive outward currentmeasured at +20mV,
where the IC50 for WT was significantly lower (1.1 mM,
R2 = 0.83, n = 7) than F255A (4.2 mM, R2 = 0.65, n = 7) and
D260 (3.8 mM, R2 = 0.89, n = 7; P , 0.01). Additionally,
we investigated if the F255A mutation interferes with
the ability of tertiapinQ to block IKACh. Figure 8D is a
compilation of 5 WT and 5 F255A mutant Kir3.1-
expressing cells, showing that the ability of tertiapinQ
to block IKAChwas not affected by the F255Amutation.
TertiapinQ (70 nM) blocked 46.2 6 5.1% of WT IKACh
and 52.3 6 11.3% of the F255A mutant IKACh (P = 0.6).
This could be a result of the fact that chloroquine binds
the channel in the intracellular domain, whereas the
tertiapinQbinding site is far away, in theextracellular loop
region (41).
Modeling of chloroquine’s interaction with
the transmembrane domain of Kir3.1
We explored with modeling whether chloroquine
binds the transmembrane domain of the channel. To do
so, a homology model for Kir3.1, using the PDB of G
protein-gated inwardly rectifying potassium channel 2
(PDB ID: 3SYO) (42), was created (Fig. 9A). Then,
docking simulations were performed, where the chlo-
roquine docking search space encompassed the entire
aqueous region of the transmembrane domain. The
simulations suggested that chloroquine (in cyan) binds
the transmembrane domain of the channel at residue
D173. The image in Fig. 9A (right) is the lowest binding-
affinity pose, shown as a bird’s-eye view from the in-
tracellular side, whereas chloroquine’s amine group
hydrogen bonds (red line) the negative side chain of
D173. As it has been demonstrated that the chloroquine
pore block of Kir2.1 channels is intracellular (43), we
explored in Fig. 9B–D if chloroquine can travel through
the channel; traverse the narrowest portion at the
G-loop formed by aa T306, G307, and M308; and reach
the transmembrane binding site at residue D173. We
calculated a voxelated version of the channel (depicted
in red) overlaying the Kir3.1 ribbon structure (gray;
F255A
F255A
F255A
F255A
F255A
A255
A255
D260
A
B
A255 A255
Figure 6. X-Ray crystallography structure of Kir3.1
with F255A mutation at 2.5 A˚ resolution and
docking of chloroquine in the mutant channel
structure. A) Left: electron density map for Kir3.1
F255A tetrameric channel after molecular re-
placement. The difference (Fo-Fc) electron density
map, around the area of residue 255, is contoured
in red at 23 s. Right: magnified view of the
residue 255 region from 1 subunit highlight-
ing the red negative-density blob, which indi-
cates the absence of residue F255. B) Docking of
chloroquine into the ion-permeation pathway of
the F255A mutant Kir3.1 channel. Left: magnified
view of the binding pose of chloroquine (cyan
sticks) in Kir3.1. Chloroquine binding is off
centered, with the amine nitrogen of chloro-
quine forming a hydrogen bond with residue
D260. The F255 residues from each of the 4 Kir3.1
subunits are shown in red sticks. Right) van der
Waals representation of the F255A mutant chan-
nel bound to chloroquine (cyan), viewed from the
intracellular side.
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Fig. 9B). Figure 9C shows the voxelated channel (red)
with the corresponding z-axis scale along the length of
the channel axis (starting at 0 A˚ at the intracellular
entrance of the intracellular aqueous vestibule). Sub-
sequently, in Fig. 9D, we calculated the aqueous ves-
tibule’s cross-sectional area as a function of the z axis
(the channel axis). The narrowest region occurs at po-
sition 37.25 A˚, at the level of the G-loop, with a cross-
sectional area of 8.25 A˚2. Figure 10A is a slice of the
voxelated channel at 37.25 A˚ (shown in red beads),
along with the surrounding corresponding residues
T306, G307, and M308. These residues are represented
as sticks (Fig. 10A, left) and as van derWaals radii (Fig.
10A, right). Subsequently, we calculated the cross-
sectional area of the chloroquine rings. It was 46.6 A˚2,
larger than the 8.25 A˚2 area of the G-loop pore. In Fig.
10B, the voxelated chloroquine is shown in blue, on top
of the G-loop. Therefore, the model suggests that it is
unlikely that chloroquine will physically pass through
the G-loop region and advance from the intracellular
region to the transmembrane domain of the aqueous
vestibule. This is in agreement with mutagenesis ex-
periments in Kir2.1 that showed that D172 (equivalent
to D173 in Kir3.1) is not involved in the chloroquine
block of Kir2.1 channels (43).
DISCUSSION
Altogether, the results demonstrate that chloroquine
terminates persistent AF and restores SR, at least in
part, by blocking IKACh via binding at a site formed
by specific amino acids in the intracellular ion-
permeation pathway. Specifically, molecular model-
ing of Kir3.1 intracellular domain interaction with
chloroquine suggested that the drug binds the aque-
ous vestibule of the channel via hydrogen bonding
and aromatic–aromatic interactions at aa F255 and
D260, in proximity to I228, Q227, and L299. 1H 15N
HSQC NMR of the purified Kir3.1 intracellular do-
main confirmed the molecular modeling predictions.
The NMR experiments showed that I228, F255, Q227,
and L299, in addition to 8 other amino acids located at
the entrance of the vestibule and by the subunit/
subunit interface, underwent significant resonance
shifts, indicating that the local environment of these
residues changed in response to chloroquine’s in-
teraction with the channel. As molecular modeling
andNMR experiments pointed to a role for F255 in the
binding of chloroquine to the channel, we mutated
that residue to alanine and crystallized and solved a
2.5 A˚ resolution X-ray structure of the mutant
F255AWTA
WT
2.5Å
B
F255A
2.5Å
C
Figure 7. Estimation of chloroquine’s ability to
block the WT and F255A mutant Kir3.1
channel using voxelation. A) Intracellular,
magnified view of the WT (left) and F255A
mutant (middle) channel’s aqueous pore with
docked chloroquine in cyan from Figs. 4 and 6,
respectively. Right: A longitudinal view of the
channel’s ribbon structure, with the orange box
indicating the area of the channel represented
by the voxelation experiments of B and C. B)
Voxelated WT channel’s ion-permeation path-
way in gray, with the front subunit removed for
clarity. Chloroquine is in cyan. The different
snapshots show a spherical voxelated probe
colored in purple, with a radius = 2.5 A˚
traveling through the channel, starting toward
the extracellular portion and getting blocked
by chloroquine. C) The voxelated F255A
mutant ion-permeation pathway is in gray, with
the front subunit removed for clarity. Chloro-
quine is in cyan. The different snapshots show a
spherical, voxelated probe colored in purple,
with a radius = 2.5 A˚ traveling down the
channel, starting toward the extracellular por-
tion, without being affected by chloroquine.
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channel. Subsequently, we performed molecular
modeling on the mutant channel to gain further in-
sights into how a small molecule blocks the ion-
permeation pathway of an inward rectifier channel.
Docking of chloroquine into the F255A Kir3.1 channel
showed an off-centered interaction of chloroquine
with themutant protein, hampering the drug’s ability
to block potassium flow through the vestibule com-
pared with the WT channel. Patch-clamp results
confirmed that F255A and D260A mutations reduced
chloroquine’s block of IKACh.
Our earlier molecular-modeling studies suggested that
chloroquine binds the intracellular domain of Kir3.1 (40).
However, the details of this binding were not fully ex-
plored. In the previous work, 10 docking runs were used.
In this study, we performed extensive simulations with
1000 runs. In general, the suggested binding site is similar
in the previous (40) and the current study.
We attempted to cocrystallize Kir3.1 in the presence of
chloroquine, butwewere unable to grow any crystals that
contained the ligand. In addition, numerous X-ray dataset
soaks of chloroquine into Kir3.1 crystals were performed,
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Figure 8. F255A and D260A mutations reduce the ability of chloroquine to block IKACh. A) Confocal microscopy. Fluorescence
staining of IKACh proteins. Top) Live HEK293 cells transfected with mCherry, WT Kir3.1, and Kir3.4. Middle (bottom): cells
transfected with mCherry, Kir3.1 F255A or D260A, and Kir3.4, where tertiapinQ ATTO-488 showed robust staining of the cell
membranes. B) BaCl2-sensitive IKACh currents elicited in WT Kir.31/Kir3.4-, F255A Kir3.1/Kir3.4-, or D260A Kir3.1/Kir3.4-
transfected cells, in response ramps from 2140 to +30 mV, before and after addition of 1 mM CQ. C, left: Dose-response curves
for the effect of chloroquine on the BaCl2-sensitive inward current measured at 2120 mV. IC50 for WT: 0.8 mM, R
2 = 0.81, n = 11;
F255A: 3.2 mM, R2 = 0.75, n = 10; and D260: 2.8 mM, R2 = 0.9, n = 10. P , 0.01 for WT vs. F255A and D260. Right: dose-response
curves for outward current measured at +20 mV. IC50 for WT: 1.1 mM, R
2 = 0.83, n = 7; F255A: 4.2 mM, R2 = 0.65, n = 7; and D260:
3.8 mM, R2 = 0.89, n = 7. P , 0.01 for WT vs. F255A and D260. D) TertiapinQ (70 nM) block of WT (46.2 6 5.1%, n = 5) and
F255A (52.3 6 11.3%, n = 5; P = 0.6) Kir3.1/ Kir3.4 currents at 2120 mV.
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but no clear ligand electron density was observed from
these experiments. Therefore, we combined molecular
modeling and 1H 15NHSQCNMR to probe the structural
basis of IKACh block by a small molecule. Comparison of
the residues affected by chloroquine binding in this work
with those of the proposed binding site for spermine from
anearlierNMRstudy (17) indicates that chloroquinebinds
to the same region. 1H 15N shifts for backbone are mostly
sensitive to changes in hydrogen-bond patterns and local
changes in secondary structure. From our NMR study, it
can be inferred that the binding of chloroquine induces
minor changes in the secondary structure of Kir3.1, as a
result of changes in the packing of side chains of amino
acids located away from the binding pocket.
A limited clinical trial in 1958 suggested that chlo-
roquine, awidely used 4-aminoquinoline antimalarial,
could be antiarrhythmic in patients with AF (44).
Oral administration of chloroquine terminated AF in
;50% of the participants. However, the antiarrhythmic
mechanism was not understood (44). Chloroquine has
been shown to block the sodium, L-type calcium and
delayed rectifier currents at concentrations higher
than used in this study (45). We used 1 mM, which is
consistentwith the plasma concentration of the drug in
patients on an antimalarial regimen (46). Nevertheless,
it is likely possible that the observed antiarrhythmic
actions of chloroquine are also a result of its ability to
block other currents, such as IK1 (47). Therefore, we
compared the electrophysiological effects of chloro-
quine with those of tertiapinQ on the dynamics of
persistent AF in the sheep heart. TertiapinQ is a potent
blocker of IKACh (14), and it was shown to prolong the
APD in atrial myocytes from patients with chronic AF
(2, 3, 5, 48). In our experiments, tertiapinQ slowed
down and terminated AF and prolonged the APD
similarly to chloroquine. This suggests that the anti-
arrhythmic effects of chloroquine can be attributed, at
least in part, to IKACh block; however, involvement of
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Figure 9. Modeling the binding of chloroquine to the Kir3.1 transmembrane domain. A) Chloroquine docking in the aqueous
region of the transmembrane domain in the homology model for Kir3.1 using the PDB of Kir3.2 (PDB ID: 3SYO). Chloroquine
(in cyan) binds the transmembrane domain of the channel at residue D173. Right: the lowest binding-affinity pose viewed from
the intracellular side. Chloroquine’s amine group hydrogen bonds (red line) the negative side chain of D173. B) Voxelated
version of the channel (in red) overlaying the Kir3.1 ribbon structure (gray). C) Voxelated channel (red) with the corresponding
z-axis scale along the length of the channel axis (starting at 0 A˚ at the intracellular entrance of the intracellular vestibule). D)
Aqueous vestibule’s cross-sectional area calculated as a function of the channel axis. The narrowest region is at 37.25 A˚, with a
cross-sectional area of 8.25 A˚2.
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other currents cannot be ruled out. For instance, the
effects of chloroquine on the dynamics of AF were
faster than those of tertiapinQ. In addition, 5/5 hearts
reverted to SR with chloroquine, whereas 4/6 hearts
terminated with tertiapin. It has been shown that IK1 is
remodeled in persistent AF (49), and thus, it is possible
that chloroquine’s action could also be a result of
blocking IK1 as well. The IC50 for chloroquine block of
IK1 and IKACh is very close as shown earlier (40). In
Kir3.1, chloroquine interacts with aa D260, and F255 in
the ion-permeation pathway, whereas in Kir2.1, it in-
teracts with equivalent aa F254 and D259, in addition
to E224 (40). Because of the similarities in the binding
of chloroquine to Kir3.1 and Kir2.1, the IC50 for chlo-
roquine block of IK1 and IKACh is similar.
It has been reported that NTC-801 (50), a benzopyrene
derivative, and AZD2927 (51), a benzamide-related com-
pound, can selectively inhibit IKACh at submicromolar con-
centrations.However, the drugs failed to revert paroxysmal
AF and atrial flutter, respectively, in patients (50, 51). The
results are not surprising, given the fact that IKACh is not
constitutively active in patients with paroxysmal AF (52),
let alone in atrial flutter whose mechanism differs from that
of AF (53). Therefore, efforts aimed at finding novel IKACh
blockers should focus on agents capable of inhibiting IKACh,
but equally as important, they should target the correct
subset ofAFpatientswhere the current has been established
to play a role. For instance, it has been argued that in clinical
trials of IKACh-blocking therapies for AF, selection of the
appropriatepatientpopulation is crucial (54).Patientswitha
high burden of paroxysmal self-terminating AF (50) are
most likely to have abnormal ectopic activity as an AF
mechanism (54); therefore, an IKACh blocker designed to
terminate reentrant AF would not be useful (54).
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